Last reviewed · How we verify

Compound sodium lactate solution

Belfast Health and Social Care Trust · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Compound sodium lactate solution is a Small molecule drug developed by Belfast Health and Social Care Trust. It is currently FDA-approved.

Compound sodium lactate solution is an intravenous fluid used in the treatment of shock, critical illness, hypotension, hypoxia, and diabetic ketoacidosis. It is often compared to other lower chloride fluids such as Hartmann's solution and Plasmalyte, as well as Ringer's lactate, in clinical trials.

At a glance

Generic nameCompound sodium lactate solution
SponsorBelfast Health and Social Care Trust
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Compound sodium lactate solution

What is Compound sodium lactate solution?

Compound sodium lactate solution is a Small molecule drug developed by Belfast Health and Social Care Trust.

Who makes Compound sodium lactate solution?

Compound sodium lactate solution is developed and marketed by Belfast Health and Social Care Trust (see full Belfast Health and Social Care Trust pipeline at /company/belfast-health-and-social-care-trust).

What development phase is Compound sodium lactate solution in?

Compound sodium lactate solution is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing